



Pharmaceuticals Pipeline

Overview and Progress / July 2026





Pharmaceuticals Pipeline Overview¹

(as of July 21, 2026)

Oncology

Cardiovascular & Renal

Neurology & Rare Diseases

Immunology

Others

Phase I

VVD KEAP1 Activator (VVD-130037 aka <i>NRF2 Inh</i> , BAY 3605349)	 NME
Actinium (225Ac) Felivotide Mopaxetan (BAY 3563254)	 NME
SOS1 Inhibitor (BAY 3498264)	 NME
PRMT5 Inhibitor (BAY 3713372)	 NME
VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171)	 NME
225Ac-GPC3 (BAY 3547926)	 NME
VVD WRN Inhibitor (VVD-133214, BAY 3772392)	 NME
KRAS G12D Inhibitor (BAY 3771249)	 NME
Dual FIIa/Xa Inhibitor (BAY 3389934)	 NME
GIRK4 Inhibitor (BAY 3670549)	NME
BAY 3620122	 NME
Ametefgene Parvec (AAV Gene Therapy) (AB-1005) Multiple System Atrophy	 NME
Pompe Disease AAV Gene Therapy (AB-1009 aka <i>PROGRESS-GT LOPD</i>)	 NME
LGMD2I/R9 AAV Gene Therapy (AB-1003 aka <i>LION-101</i>)	 NME
Primary Photoreceptor Diseases Cell Therapy (BRT-OpCT-001)	 NME
AT-05 SPECT Tracer	 NME

Phase II

Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088) // Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)	 IE
Umiposgene Parvec (AAV Gene Therapy) (AB-1002) // Congestive Heart Failure (GenePHIT)	 NME
Inclocibart (anti-a2AP) (BAY 3018250) // Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)	 NME
Nurandociguat (sGC Activator Oral) (BAY 3283142) // Chronic Kidney Disease (ALPINE-1)	 NME
SEMA 3a Inhibitor (BAY 3401016) // Alport Syndrome (ASSESS)	 NME
Ametefgene Parvec (AAV Gene Therapy) (AB-1005) // Parkinson's Disease (REGENERATE-PD)	 NME
Edonentan (ER Antagonist) (PER-001, BAY 3826827) // Non-proliferative Diabetic Retinopathy // Glaucoma	 NME

Phase III

Darolutamide (AR Inhibitor) // Adjuvant Prostate Cancer (DASL-HiCaP) // Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)	 IE
Finerenone (MR Antagonist) // Non-diabetic Chronic Kidney Disease (FIND-CKD)	 IE
Bemdaneprocel (Cell Therapy) // Parkinson's Disease (exPDite-2)	 NME
124I-Evuzamitide (PET Tracer) // Diagnosis of Cardiac Amyloidosis (REVEAL)	 NME

Submissions

Sevabertinib (HER2/mEGFR Inhibitor) // CN, US: Advanced NSCLC 1L // JP: HER2-mut NSCLC 2L	 IE  NME
Finerenone (MR Antagonist) // US: Chronic Kidney Disease in Type 1 Diabetes	 IE
Asundexian (FXIa Inhibitor) // CN, EU, JP, US: 2° Stroke Prevention	 NME
Aflibercept 8mg (VEGF-Inhibitor) // CN: Retinal Vein Occlusion	 IE
Gadoquatrane (High Relaxivity Contrast Agent) // EU, CN: Magnetic Resonance Imaging	 NME

 Small Molecule  Radionuclide Therapy  Genetic Therapy  Cell Therapy  Imaging Agent  Protein Therapy

NME New Molecular Entity IE Indication Expansion

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit



Pharmaceuticals Pipeline Details Oncology¹

(as of July 21, 2026)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Darolutamide (AR Inhibitor)	Adjuvant Prostate Cancer (<i>DASL-HiCaP</i>)					NCT04136353	Q1 2028	Study ongoing
	Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (<i>ARASTEP</i>)					NCT05794906	Q3 2027	Study ongoing
Sevabertinib (HER2/mEGFR Inhibitor) (<i>BAY 2927088</i>)	Metastatic or Unresectable Solid Tumors with HER2-activating Mutations (<i>panSOHO</i>)					NCT06760819	Q1 2027	Study ongoing
VVD KEAP1 Act (<i>VVD-130037 aka NRF2 Inh, BAY 3605349</i>)	Advanced Solid Tumors					NCT05954312	Q3 2030	Study ongoing
Actinium (225Ac) Felivotide Mopaxetan (<i>BAY 3563254</i>)	Advanced Prostate Cancer					NCT06217822	Q4 2028	Study ongoing
SOS1 Inhibitor (<i>BAY 3498264</i>)	Advanced Solid Cancers					NCT06659341	Q1 2027	Study ongoing
PRMT5 Inhibitor (<i>BAY 3713372</i>)	MTAP-deleted Solid Tumors					NCT06914128	Q2 2029	Study ongoing
VVD RAS-PI3K Inhibitor (<i>VVD-159642, BAY 3674171</i>)	Advanced Solid Tumors					NCT06804824	Q3 2027	Study ongoing
225Ac-GPC3 (<i>BAY 3547926</i>)	Advanced Liver Cancer					NCT06764316	Q3 2029	Study ongoing
VVD WRN Inhibitor (<i>VVD-133214, BAY 3772392</i>)	Advanced Solid Tumors					NCT06004245	Q2 2027	Study ongoing
KRAS G12D Inhibitor (<i>BAY 3771249</i>)	Advanced Solid Tumors					NCT07207707	Q3 2026	Study ongoing

 Small Molecule  Radionuclide Therapy  Genetic Therapy  Cell Therapy  Imaging Agent  Protein Therapy

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit



Pharmaceuticals Pipeline Details Cardiovascular & Renal¹

(as of July 21, 2026)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Finerenone (MR Antagonist)	Non-diabetic CKD (<i>FIND-CKD</i>)					NCT05047263	Q4 2025	Study completed
Umiposgene Parvec (AAV Gene Therapy) (<i>AB-1002</i>)	Congestive Heart Failure (<i>GenePHIT</i>)					NCT05598333	Q4 2026	Study ongoing
Inclocibart (anti-a2AP) (<i>BAY 3018250</i>)	Acute Ischemic Stroke; Pulmonary Embolism (<i>SIRIUS</i>)					NCT06149520	Q4 2025	Study completed
Nurandociguat (sGC Act. Oral) (<i>BAY 3283142</i>)	Chronic Kidney Disease (CKD) (<i>ALPINE 1</i>)					NCT06522997	Q4 2025	Study completed
SEMA 3a (<i>BAY 3401016</i>)	Alport Syndrome (<i>ASSESS</i>)					NCT07211685	Q3 2028	Study ongoing
Dual FIIa/Xa Inhibitor (<i>BAY 3389934</i>)	Sepsis-Induced Coagulopathy					NCT06854640	Q4 2026	Study ongoing
GIRK4 Inhibitor (<i>BAY 3670549</i>)	Atrial fibrillation	Undisclosed				n/a	Q4 2025	Study completed
BAY 3620122	Vasoplegia					n/a	Q4 2026	Study ongoing

 Small Molecule  Radionuclide Therapy  Genetic Therapy  Cell Therapy  Imaging Agent  Protein Therapy

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit



Pharmaceuticals Pipeline Details Neurology & Rare Diseases¹

(as of July 21, 2026)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Bemdaneprocel (Parkinson's Disease Cell Therapy)	Parkinson's Disease (<i>exPDite-2</i>)					NCT06944522	Q1 2027	Study ongoing
Ametefgene Parvec (AAV Gene Therapy) (<i>AB-1005</i>)	Parkinson's Disease (<i>REGENERATE-PD</i>)					NCT06285643	Q3 2028	Study ongoing
	Multiple System Atrophy					NCT04680065	Q3 2026	Study ongoing
Pompe Disease AAV Gene Therapy (<i>AB-1009 aka PROGRESS-GT LOPD</i>)	Pompe Disease					NCT07282847	Q3 2028	Study ongoing
LGMD2I/R9 AAV Gene Therapy (<i>AB-1003 aka LION-101</i>)	Limb-Girdle Muscular Dystrophy 2i					NCT05230459	Q4 2028	Study ongoing

 Small Molecule  Radionuclide Therapy  Genetic Therapy  Cell Therapy  Imaging Agent  Protein Therapy

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit



Pharmaceuticals Pipeline Details Others¹

(as of July 21, 2026)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
124I-Evuzamitide (PET Tracer)	Diagnosis of Cardiac Amyloidosis (<i>REVEAL</i>)					NCT06788535	Q2 2026	Study completed
Edonentan (<i>PER-001, BAY 3826827</i>)	Non-proliferative Diabetic Retinopathy					NCT06003751	Q2 2025	Study completed
	Glaucoma					NCT05822245	Q2 2025	Study completed
Primary Photoreceptor Diseases Cell Therapy (<i>BRT-OpCT-001</i>)	Primary Photoreceptor Disease					NCT06789445	Q4 2029	Study ongoing
AT-05 SPECT Tracer	Diagnosis of Cardiac Amyloidosis					NCT05951816	n/a	n/a

 Small Molecule  Radionuclide Therapy  Genetic Therapy  Cell Therapy  Imaging Agent  Protein Therapy

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit